Event-Free Survival at 12 Months Predicts Long-Term Outcomes in DLBCL Patients Receiving CAR-T Therapy

Key Points

• Event-free survival at 12 months significantly protects the likelihood of positive long-term outcomes in DLBCL patients receiving CAR-T therapy.
• The analysis highlights a notable correlation, with a specific focus on outcomes post-therapy within a 12-month timeframe.
• Assessment using clinical data from DLBCL patients treated with CAR-T therapy reveals patterns in long-term survival rates.
• Further validation is needed to confirm these findings and their applicability across diverse patient populations.